Search clinical trials for: Gemcitabine , Docetaxel

Total 5004 results

Korean Breast Cancer Study Group

Unknown

Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast Cancer (NeoTG)

Breast Cancer Stage II | Breast Cancer Stage III

Korea, Republic of
Sanofi

Completed

Docetaxel in Non Small Cell Lung Cancer (NSCLC)

Lung Neoplasms

Spain
Sun Yat-sen University

Recruiting

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

Nasopharyngeal Carcinoma

China
Spanish Lung Cancer Group

Terminated

Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma (BREC)

Non Small Cell Lung Cancer | BRCA1 Mutation

Spain
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States, Puerto Rico, South Africa
Sanofi

Completed

Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer

Italy
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas

Pancreatic Cancer

United States
Shanghai Jiao Tong University School of Medicine
Shanghai 10th People's Hospital; Jiangxi Provincial Cancer Hospital; Shanghai... and other collaborators

Recruiting

A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer (CCODG-NSCLC)

Recurrent Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sanofi

Completed

ADVANCED Phase II Trial of Weekly vs 3 Weekly Docetaxel and Cisplatin Followed by Gemcitabine in Non-small-cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Italy
Sanofi

Completed

GILT Docetaxel - Non-Small Cell Lung Cancer

Lung Neoplasms

Spain, Germany, Switzerland
Medical University of South Carolina
Novartis

Completed

A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

Sarcoma

United States
Clinical Hospital Centre Zagreb

Active, not recruiting

Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer

Croatia
Nanjing Leads Biolabs Co.,Ltd

Recruiting

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Malignant Tumors

China
National Health Research Institutes, Taiwan
Mackay Memorial Hospital; China Medical University Hospital; Buddhist Tzu Chi... and other collaborators

Completed

Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Advanced/Metastatic Malignant GIST (STS)

Sarcoma | Malignant Gastrointestinal Stromal Tumor

Taiwan
Herlev Hospital
Eli Lilly and Company; Sanofi

Completed

Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer

Prostate Cancer

Denmark
Central European Cooperative Oncology Group

Completed

Study Comparing Concomitant Docetaxel + Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine

Breast Cancer

Bulgaria, Austria, Czech Republic, Israel, Lebanon, Poland, Slovakia
Columbia University

Unknown

Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)

Pancreatic Cancer Stage III | Pancreatic Cancer Stage II

United States
Samsung Medical Center

Completed

Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer

Metastatic Carcinoma | Recurrent Esophageal Squamous Cell Carcinoma

Korea, Republic of
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer
University of Southern California
Eli Lilly and Company; Aventis Pharmaceuticals

Completed

Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma

Peritoneal Neoplasms | Ovarian Carcinoma

United States
Asan Medical Center
Samsung Medical Center; Korea University Anam Hospital; Severance Hospital

Unknown

Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy

Sarcoma
GERCOR - Multidisciplinary Oncology Cooperative...

Unknown

Gemcitabine and Docetaxel in Treating Patients With Inoperable Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

France
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer

Liver Cancer

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Docetaxel and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Lung Cancer

United States
Samsung Medical Center

Unknown

Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary

Carcinoma of Unknown Primary

Korea, Republic of
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer

Prostate Cancer

United States
Hospital Arnau de Vilanova

Unknown

Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non-Small Cell Lung Cancer (NSCLC) Patients

Carcinoma, Non-Small-Cell Lung

Spain
Institut de Recherches Internationales Servier

Terminated

Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

Lymphoma | Advanced Solid Tumors

United States, Spain, France
UNICANCER

Completed

Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma

Sarcoma

France
Amgen

Unknown

Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

United States
Hospital Arnau de Vilanova

Unknown

Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

Carcinoma, Non-Small-Cell Lung

Spain
University of Southern California
Sanofi

Terminated

Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.

Pancreatic Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
Sun Yat-sen University

Recruiting

Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC

Nasopharyngeal Carcinoma | Circulating Tumor Cell | Effects of Chemotherapy | Distant Metastases.Clinical

China
Duke University
Eli Lilly and Company

Terminated

Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer (TOP0602)

Non Small Cell Lung Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma

Sarcoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma

Sarcoma | Small Intestine Cancer | Ovarian Cancer

United States
Eli Lilly and Company

Completed

Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents

Breast Neoplasms

France, Germany, Italy, Netherlands, Spain, United Kingdom
H. Lee Moffitt Cancer Center and Research Institute
Sanofi

Terminated

Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery

Pancreatic Neoplasms

United States
Columbia University

Completed

Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar

Pancreatic Cancer Stage IVA

United States
Spanish Lung Cancer Group

Completed

Randomized Customized Adjuvant Chemotherapy (GECP-SCAT) (GECP-SCAT)

Non-small-cell Lung Cancer

Spain
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

Sarcoma | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Bladder Cancer | Melanoma (Skin) | Carcinoma of Unknown Primary

United States
National Taiwan University Hospital

Completed

Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

Taiwan
Boehringer Ingelheim

Completed

A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel

Neoplasms

France
University of Pittsburgh
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Lung Cancer

United States
Beth Israel Deaconess Medical Center

Completed

Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Cavity Cancer

United States
European Organisation for Research and Treatment...

Completed

Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

Pancreatic Cancer

France, Poland, Belgium, Germany, Egypt, Netherlands, United Kingdom, Turkey
Eli Lilly and Company

Completed

A Phase III Trial For Patients With Metastatic Breast Cancer

Breast Cancer | Breast Neoplasms | Cancer of the Breast

United States, Argentina, Australia, Brazil, Korea, Republic of, Mexico, Puerto Rico, Taiwan

Search clinical trials for: Gemcitabine , Docetaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations